GlassScriptPhysician profile
Wren Vines
NPI 1245776343
$5,046.65
in general payments reported to CMS, 2019-2025
22 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $495 · 2022: $2,122 · 2023: $1,619 · 2024: $693 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.83 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $739.03 | 2021-2025 | Entyvio, Trintellix, Gattex |
| Celgene Corporation | $683.82 | 2021-2024 | Zeposia |
| Janssen Scientific Affairs, LLC | $441.74 | 2022-2023 | Stelara |
| Daiichi Sankyo INC. | $312.52 | 2021-2023 | Injectafer |
| Pfizer INC. | $302.36 | 2021-2023 | |
| Janssen Biotech, INC. | $279.98 | 2021-2023 | Stelara, Simponi, Simponi Aria |
| Merz North America, INC. | $200.20 | 2024 | |
| Revance Therapeutics, INC. | $183.98 | 2024-2025 | Daxxify |
| Lilly USA, LLC | $132.10 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $75.33 | 2021-2023 | Dificid |
| Pharmacosmos Therapeutics INC. | $49.71 | 2021-2023 | Monoferric |
| Galderma Laboratories, L.P. | $49.30 | 2024 | Dysport |
| Amgen INC. | $34.98 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.00 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $28.39 | 2021-2022 | |
| Qol Medical, LLC | $25.43 | 2023 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $18.54 | 2022 | |
| Intercept Pharmaceuticals, INC. | $16.66 | 2023 | Ocaliva |
| Ardelyx, INC. | $16.44 | 2023 | Ibsrela |
| Fresenius Kabi USA, LLC | $14.46 | 2023 | Idacio |
| Redhill Biopharma INC. | $12.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wren Vines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.